FDA OK's Boehringer's Stiolto Respimat in COPD

The FDA has given Boehringer Ingelheim the go-ahead to market Stiolto Respimat (tiotropium bromide and olodaterol) as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.